A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510548-19-00

Acronym

CF102-212LD

Enrollment

Registered

2024-11-11

Start date

2023-03-02

Completion date

Unknown

Last updated

2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

Brief summary

Proportion of subjects who achieve a ≥2-point improvement in NAS (Week 36, relative to Baseline)

Detailed description

The mean PCFB in serum ALT level (Week 36, relative to Baseline)

Interventions

DRUGNamodenoson

DRUGMatching placebo for namodenoson

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of subjects who achieve a ≥2-point improvement in NAS (Week 36, relative to Baseline)	—

Secondary

Measure	Time frame
The mean PCFB in serum ALT level (Week 36, relative to Baseline)	—

Countries

Bulgaria, Romania

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026